Obesity Drug Competition 2026: Lilly, Novo Nordisk and the Next Wave of Weight-Loss Therapies
The obesity-drug market has entered a new phase. Eli Lilly and Novo Nordisk remain central to the global obesity-treatment market, but the competitive landscape in 2026 is no longer simply a two-company race between tirzepatide and semaglutide.
Oral GLP-1 therapies are now commercial products. Next-generation dual and triple agonists have generated substantial clinical weight-loss results. Amylin-based medicines have moved into late-stage development. Long-acting therapies are testing less-frequent dosing, while combination strategies are attempting to address multiple biological pathways simultaneously.
Important: Clinical-stage drugs discussed in this article are investigational unless explicitly identified as approved. Weight-loss percentages reported from different clinical trials should not be interpreted as direct head-to-head comparisons unless the drugs were tested against each other in the same randomized trial. Many figures below come from company-reported topline data and may change following full publication, regulatory review or additional analyses.
- How the obesity-drug market has changed
- 2026 obesity pipeline snapshot
- Eli Lilly
- Novo Nordisk
- Roche and Zealand Pharma
- AstraZeneca
- Amgen
- Boehringer Ingelheim and Zealand Pharma
- Regeneron
- Viking Therapeutics
- Structure Therapeutics
- Kailera and Hengrui Pharma
- How to compare the next generation of obesity drugs
- What the next obesity market may look like
- FAQ
How the obesity-drug market has changed
The first modern wave of obesity medicines established GLP-1 receptor agonism as one of the most important pharmacological approaches to chronic weight management. Semaglutide demonstrated the potential of GLP-1 therapy in obesity, while tirzepatide added GIP receptor activity and produced a new benchmark for weight reduction in clinical trials.
.png)
By 2026, however, the field has expanded beyond conventional weekly GLP-1 injections.
There are now several major development strategies:
- GLP-1 monotherapy: injectable and oral approaches such as semaglutide and orforglipron.
- GLP-1/GIP dual agonists: including tirzepatide and multiple investigational competitors.
- GLP-1/GIP/glucagon triple agonism: exemplified by retatrutide.
- Amylin-based therapies: including petrelintide and cagrilintide-based combinations.
- Combination therapies: pairing incretin biology with amylin or other metabolic mechanisms.
- Long-acting approaches: attempting monthly, every-eight-week or even quarterly maintenance schedules.
- Oral small molecules: designed to provide peptide-like metabolic effects without an injection.
This is an important change in how the market should be analyzed. The question is no longer simply which company can produce the largest percentage of weight loss.
The more useful questions include:
- How much weight loss can be achieved?
- How well is treatment tolerated?
- Can weight loss be maintained long term?
- Can the treatment be administered orally?
- Can injections be given less frequently?
- Can lean mass and physical function be better preserved?
- Can treatment improve cardiovascular, metabolic, liver or sleep-related complications?
- Can manufacturing, supply and pricing support very large patient populations?
2026 obesity pipeline snapshot
| Company | Important obesity asset(s) | Core approach | October 2026 status |
|---|---|---|---|
| Eli Lilly | Zepbound; Foundayo; retatrutide; EloraTZP | GIP/GLP-1; oral GLP-1; GIP/GLP-1/glucagon; amylin + tirzepatide | Approved products plus multiple late-stage programs |
| Novo Nordisk | Wegovy; Wegovy pill; CagriSema; zenagamtide | GLP-1; oral GLP-1; GLP-1 + amylin; next-generation GLP-1/amylin | Approved products plus late-stage and mid-stage pipeline |
| Roche | Enicepatide; petrelintide; combinations | GLP-1/GIP; amylin; incretin + amylin | Phase 3 and expanding combination programs |
| AstraZeneca | Elecoglipron; AZD6234; AZD9550 | Oral GLP-1; amylin; glucagon/GLP-1 | Mid- and late-stage development |
| Amgen | MariTide | Long-acting GLP-1 receptor activation with GIP receptor antagonism | Phase 3 |
| Boehringer Ingelheim / Zealand | Survodutide | GLP-1/glucagon dual agonist | Phase 3 |
| Regeneron | Olatorepatide and other metabolic programs | GLP-1/GIP and additional body-composition strategies | Late-stage development |
| Viking Therapeutics | VK2735; VK3019 | GLP-1/GIP; amylin-related | Phase 3 plus early-stage pipeline |
| Structure Therapeutics | Aleniglipron; ACCG-2671 | Oral GLP-1; oral amylin receptor agonist | Phase 3 plus early-stage development |
| Kailera / Hengrui | Ribupatide | GLP-1/GIP dual agonist, injectable and oral | Late-stage development |
↔ Swipe the table sideways to see all columns on mobile.
Development status refers to information publicly available by October 3, 2026 and can change as trials, regulatory filings and company programs evolve.
Eli Lilly: expanding from tirzepatide into multiple next-generation mechanisms
Eli Lilly's current obesity platform includes Zepbound (tirzepatide) and the oral GLP-1 receptor agonist Foundayo (orforglipron). The company is also developing next-generation agents intended to extend the biological reach of incretin therapy.
Foundayo: oral GLP-1 becomes a commercial reality
On April 1, 2026, the U.S. Food and Drug Administration approved Foundayo (orforglipron) for adults with obesity or overweight with at least one weight-related comorbidity, in combination with a reduced-calorie diet and increased physical activity.
The approval is important for the competitive landscape because it moves oral GLP-1 therapy from a pipeline experiment to an established treatment category. FDA announcement.
Retatrutide: triple-pathway development
Lilly's retatrutide is an investigational triple agonist targeting GIP, GLP-1 and glucagon receptors.
In the Phase 3 TRIUMPH-1 trial, Lilly reported that participants receiving 12 mg retatrutide achieved an average 28.3% weight loss at 80 weeks, while 45.3% achieved at least 30% weight loss. These are company-reported topline results and remain subject to the usual limitations associated with interpreting investigational clinical-trial data before regulatory review and full publication.
The program therefore represents one of the clearest attempts to move beyond conventional GLP-1/GIP dual agonism toward a three-pathway metabolic strategy. Lilly retatrutide update.
EloraTZP: tirzepatide plus amylin biology
Lilly is also exploring combinations rather than simply replacing tirzepatide.
EloraTZP combines tirzepatide with eloralintide, a selective amylin receptor agonist.
In a 48-week Phase 2b study involving adults with obesity or overweight and type 2 diabetes, Lilly reported average weight loss of up to 23.3% with EloraTZP compared with 14.8% with tirzepatide 15 mg. Lilly said Phase 3 development would begin in the fourth quarter of 2026.
The program illustrates the increasingly important concept of multi-mechanism obesity therapy: combine different physiological pathways rather than relying on one dominant receptor system. Lilly EloraTZP update.
Key Lilly theme: Lilly's development strategy is increasingly diversified across an established injectable dual agonist, an approved oral GLP-1, triple agonism and amylin/incretin combinations.
Novo Nordisk: semaglutide remains central while amylin becomes increasingly important
Novo Nordisk helped establish semaglutide as a major obesity-treatment platform. By 2026, however, the company is also attempting to extend that platform through oral treatment, higher-dose semaglutide and amylin-based combinations.
Wegovy pill: oral semaglutide
The FDA approved once-daily oral semaglutide 25 mg under the Wegovy brand in December 2025. Novo launched the Wegovy pill broadly in the United States on January 5, 2026.
Novo reported approximately 17% average weight loss in the OASIS 4 trial when evaluating the treatment effect assuming patients remained on treatment, and approximately 14% using the treatment-regimen approach. These figures come from the company's reporting of the clinical program.
The commercial significance is considerable: oral semaglutide creates a direct oral alternative within Novo's existing obesity franchise. Novo regulatory announcement and Wegovy pill launch information.
CagriSema: GLP-1 plus amylin
CagriSema combines semaglutide with the long-acting amylin analogue cagrilintide.
In REDEFINE 9, Novo reported 21% weight loss versus 2% with placebo at week 68 with a lower-dose maintenance regimen. In REIMAGINE 5, a lower-dose CagriSema regimen produced 12.4% weight loss versus 9.1% with tirzepatide 5 mg at week 60 in adults with type 2 diabetes.
These results should be read as separate clinical questions rather than combined into a single league table. REDEFINE 9 and REIMAGINE 5. (Sep 2026)
The broader Novo strategy
Novo's pipeline illustrates a transition from a single dominant mechanism toward a broader portfolio of semaglutide, oral treatment and amylin-based approaches.
The company is also developing zenagamtide, formerly known as amycretin, a next-generation GLP-1/amylin-based therapy.
Key Novo theme: The company's competitive position increasingly depends on extending semaglutide into oral, higher-dose and multi-mechanism formats while developing new pathways beyond conventional GLP-1 monotherapy.
Roche and Zealand Pharma: building a dual-agonist and amylin platform
Roche has become one of the most active large pharmaceutical companies in obesity development through a portfolio centered on enicepatide, petrelintide and combination strategies.
Enicepatide
Enicepatide, formerly CT-388, is an investigational once-weekly dual GLP-1/GIP receptor agonist.
In a Phase 2 study of adults with obesity or overweight without type 2 diabetes, Roche reported placebo-adjusted weight loss of 22.5% at 48 weeks at the highest tested dose.
In a separate Phase 2 study involving people with type 2 diabetes and overweight or obesity, the highest 24 mg dose produced mean weight loss of 15.5% at 48 weeks, together with a reported mean HbA1c reduction of 2.65%.
Roche has advanced enicepatide into Phase 3 studies ENITH-1 and ENITH-2 for chronic weight management. January 2026 Phase 2 results and September 2026 Phase 2 results.
Petrelintide
Petrelintide is an investigational human amylin analogue developed by Zealand Pharma in collaboration with Roche.
Zealand reports that petrelintide has now moved into registrational Phase 3 development for chronic weight management. The Phase 2 program was designed to evaluate adults with overweight or obesity both with and without type 2 diabetes.
This program is particularly relevant because amylin is becoming one of the most important alternative or complementary pathways in the next generation of obesity therapy. Zealand petrelintide pipeline.
Enicepatide plus petrelintide
Roche is also evaluating the combination of the dual incretin agonist enicepatide and petrelintide.
The concept is straightforward: use complementary metabolic pathways to potentially increase efficacy while attempting to maintain acceptable tolerability.
Whether such combinations ultimately offer a clinically meaningful advantage will depend on randomized Phase 3 evidence rather than mechanistic rationale alone.
Key Roche/Zealand theme: The portfolio combines two important next-generation mechanisms — GIP/GLP-1 and amylin — while also exploring their combination.
AstraZeneca: an oral and multi-mechanism strategy
AstraZeneca is pursuing a broad metabolic portfolio rather than concentrating on a single obesity candidate.
Elecoglipron
Elecoglipron is an oral small-molecule GLP-1 receptor agonist.
The attraction of the approach is obvious: an orally administered small molecule could eliminate injections while targeting the same broad GLP-1 pathway.
AstraZeneca has also expanded its obesity platform through external partnerships and additional mechanisms, including amylin and glucagon-related programs.
Additional metabolic programs
The company's broader pipeline includes candidates such as:
- AZD6234: an amylin-related obesity program.
- AZD9550: a GLP-1/glucagon dual agonist.
- Additional oral and longer-acting metabolic programs acquired or developed through partnerships.
This portfolio approach is important because the future obesity market may contain several commercially meaningful treatment classes rather than a single universal mechanism.
AstraZeneca's strategy also highlights an important distinction between pipeline breadth and clinical validation. A large portfolio can create multiple opportunities, but individual candidates still have to demonstrate efficacy, safety, durability and regulatory feasibility.
Amgen: testing whether less-frequent dosing can change obesity treatment
Amgen's MariTide (maridebart cafraglutide) is one of the most distinctive programs in the obesity pipeline because its long-acting design could allow substantially less-frequent administration than the conventional weekly model.
MariTide is designed around GLP-1 receptor activation combined with GIP receptor antagonism and is being developed with monthly, every-eight-week and quarterly maintenance strategies.
Amgen's Phase 3 program includes chronic weight management as well as studies involving cardiovascular outcomes, heart failure and obstructive sleep apnea. The company is also studying switching patients from weekly semaglutide or tirzepatide to less-frequent MariTide schedules.
The importance of MariTide therefore extends beyond percentage weight loss.
The key question is whether a much less-frequent treatment schedule can deliver an acceptable combination of:
- clinically meaningful weight reduction,
- long-term maintenance,
- acceptable tolerability,
- treatment convenience, and
- outcomes across obesity-related complications.
Key Amgen theme: dosing frequency itself may become a major competitive variable if long-acting therapies can maintain effectiveness with fewer administrations.
Boehringer Ingelheim and Zealand Pharma: survodutide moves into the evidence stage
Survodutide is an investigational dual GLP-1/glucagon receptor agonist developed by Boehringer Ingelheim in partnership with Zealand Pharma.
The rationale differs from a conventional GLP-1/GIP strategy because glucagon receptor activity is intended to influence energy expenditure and broader metabolic physiology in addition to appetite and glucose control.
The Phase 3 program has now produced important results.
In the Phase 3 SYNCHRONIZE-2 trial involving adults with obesity or overweight and type 2 diabetes, Boehringer reported up to 13.1% average weight loss at 76 weeks using the efficacy estimand, compared with 3.1% with placebo.
The trial also reported substantial improvements in the proportion of participants achieving at least 5% weight loss.
Full SYNCHRONIZE-2 results were presented at the 2026 European Association for the Study of Diabetes meeting and published simultaneously in The New England Journal of Medicine.
Boehringer Phase 3 SYNCHRONIZE-2 results.
Key survodutide theme: glucagon biology provides a distinct mechanism from the increasingly crowded GLP-1/GIP field and may be especially relevant to broader metabolic disease.
Regeneron: combining obesity pharmacology with a broader metabolic strategy
Regeneron's obesity portfolio includes olatorepatide, a GLP-1/GIP dual receptor agonist licensed from Hansoh Pharmaceutical Group.
In a Phase 3 study in China, Hansoh reported up to 19% body-weight loss at week 48. Regeneron said its global Phase 3 registrational program would begin later in 2026.
The Chinese Phase 3 trial enrolled 604 adults across 33 clinical sites and compared once-weekly olatorepatide with placebo over 48 weeks.
Regeneron olatorepatide Phase 3 update.
Regeneron's broader strategy has also included interest in body composition and preservation of lean tissue during weight loss.
This is an increasingly important development area.
Future obesity treatments may be judged not only by how much body weight is lost, but by the biological composition of that loss:
- fat mass reduction,
- visceral fat reduction,
- preservation of skeletal muscle,
- maintenance of physical function, and
- long-term metabolic health.
Viking Therapeutics: GLP-1/GIP plus less-frequent maintenance
Viking Therapeutics has become increasingly important in the clinical-stage obesity landscape through VK2735, a GLP-1/GIP dual agonist being developed in injectable and oral forms.
In September 2026, Viking reported new maintenance data showing approximately 22% weight loss at week 33 in an exploratory group continuing weekly VK2735 after induction. The company also reported that participants switching to every-other-week or monthly regimens maintained a large proportion of the weight loss achieved during weekly induction.
For monthly dosing, Viking reported maintenance of up to 90% of the weight loss achieved during the induction period over the three-month maintenance phase in the analyzed groups.
These findings remain company-reported exploratory clinical data rather than evidence from a completed head-to-head Phase 3 comparison with marketed obesity therapies. Nevertheless, they illustrate the increasing industry focus on dosing frequency and maintenance.
Viking is also developing VK3019, an early-stage amylin-related program.
Viking September 2026 maintenance study.
Key Viking theme: the company is attempting to compete across both efficacy and treatment convenience while also building an amylin pipeline.
Structure Therapeutics: the oral small-molecule challenge
Structure Therapeutics is developing aleniglipron, an oral small-molecule GLP-1 receptor agonist.
Oral small molecules are strategically important because they could potentially make incretin therapy easier to administer and scale while reducing dependence on injectable peptide manufacturing.
Structure reported up to 16.2% mean body-weight reduction at 72 weeks in the ACCESS open-label extension and reported that the Phase 3 ACCOMPLISH program for chronic weight management was underway.
The company is also developing ACCG-2671, an oral small-molecule amylin receptor agonist.
This creates an interesting two-track strategy: develop an oral GLP-1 while simultaneously exploring oral amylin biology.
Structure September 2026 update and Structure Phase 3 update.
Kailera and Hengrui Pharma: a globalizing obesity pipeline
The obesity-drug race is becoming increasingly international, and China has become an important source of clinical candidates and pharmaceutical partnerships.
Ribupatide, developed by Hengrui Pharma and being advanced with Kailera Therapeutics, is a GLP-1/GIP dual receptor agonist available in both injectable and oral development programs.
At the 2026 American Diabetes Association Scientific Sessions, Hengrui and Kailera presented Phase 2 obesity data for oral ribupatide showing mean weight loss of up to 12.1% at 26 weeks, with continued weight reduction and no observed plateau over the study period.
Hengrui has also reported positive Phase 3 data for injectable ribupatide in type 2 diabetes in China.
The broader significance is that the next generation of obesity medicines is increasingly being developed through multinational partnerships rather than exclusively by U.S. or European pharmaceutical companies.
Hengrui and Kailera ribupatide data and Hengrui Phase 3 update.
How to compare the next generation of obesity drugs
A simple ranking system is increasingly inadequate for evaluating this field.
A better framework is to compare each medicine across multiple dimensions.
↔ Swipe the table sideways to see all columns on mobile.
| Dimension | Why it matters | Questions to ask |
|---|---|---|
| Weight loss | Central clinical outcome | What was the percentage reduction, at what time point and in which population? |
| Comparator | Determines how the result should be interpreted | Was the study placebo-controlled or head-to-head? |
| Trial duration | Short-term weight loss may not predict long-term maintenance | Were outcomes measured at 24, 48, 68, 76, 80 or more weeks? |
| Tolerability | Adverse effects can influence persistence | What gastrointestinal and other adverse events occurred? How many discontinued? |
| Route | Administration can affect convenience and uptake | Injection or oral? |
| Dosing frequency | Less-frequent therapy may improve convenience | Weekly, every two weeks, monthly, every eight weeks or quarterly? |
| Weight maintenance | Obesity is generally treated as a chronic disease | Can weight reduction be maintained over time? |
| Body composition | Scale weight does not describe the full biological effect | How much fat versus lean mass is lost? |
| Metabolic effects | Obesity treatment increasingly targets overall cardiometabolic risk | What happens to glucose, blood pressure, lipids and other markers? |
| Comorbidity outcomes | Clinical value may extend beyond weight reduction | Are cardiovascular disease, diabetes, sleep apnea, fatty liver or other outcomes improved? |
| Manufacturing | Mass-market obesity therapy requires enormous supply capacity | Can the product be manufactured at global scale? |
| Regulatory status | Pipeline promise is not the same as an approved treatment | Is it preclinical, Phase 1, Phase 2, Phase 3, filed or approved? |
Why cross-trial weight-loss rankings can be misleading
Suppose Drug A produces 22% average weight loss and Drug B produces 19%. It would be tempting to place Drug A above Drug B.
That conclusion may be wrong.
The studies might differ in:
- baseline BMI and body weight,
- presence or absence of diabetes,
- treatment duration,
- dose escalation schedules,
- dropout rates,
- statistical estimands,
- background lifestyle intervention, and
- whether participants were required to remain on treatment.
The CagriSema REDEFINE 4 trial provides a useful real-world illustration. Novo reported 23.0% weight loss with CagriSema versus 25.5% with tirzepatide 15 mg under one analysis, yet CagriSema did not meet its predefined non-inferiority endpoint. That is far more informative than simply saying that CagriSema produced “23% weight loss.”
What the next obesity market may look like
1. Oral GLP-1 medicines will become a major competitive category
With oral semaglutide and orforglipron already approved in the United States, oral GLP-1 treatment is no longer merely a speculative pipeline concept.
The next question is whether additional oral drugs can achieve an attractive combination of efficacy, tolerability, convenience and long-term adherence.
2. GLP-1/GIP may become one platform rather than one product
Tirzepatide demonstrated the commercial and clinical power of dual GIP/GLP-1 receptor agonism. Multiple companies are now developing similar or related mechanisms.
That means differentiation may increasingly shift toward:
- higher or more durable efficacy,
- tolerability,
- oral administration,
- less-frequent dosing,
- combination therapy, and
- outcomes beyond weight loss.
3. Amylin may become one of the most important next-generation mechanisms
Amylin is now being explored by several major developers, including Novo Nordisk, Lilly, Roche/Zealand, AstraZeneca, Viking and Structure Therapeutics.
CagriSema, petrelintide, EloraTZP and other programs provide multiple tests of whether amylin can complement incretin-based therapy.
The key scientific question is not simply whether amylin produces weight loss by itself. It is whether amylin-based therapy can add clinically meaningful benefits when combined with existing incretin approaches.
4. Triple agonism is moving toward the clinic
Retatrutide demonstrates the ambition behind triple-pathway therapy.
The combination of GIP, GLP-1 and glucagon receptor activity is designed to influence several components of energy regulation simultaneously.
Its Phase 3 results have generated substantial interest, but regulatory evaluation, full publication and broader safety and efficacy data remain essential before drawing conclusions about its eventual place in clinical practice.
5. Less-frequent dosing could become a major differentiator
Amgen's MariTide and Viking's VK2735 are two examples of programs investigating treatment schedules that extend beyond conventional weekly dosing.
This matters because obesity therapy is generally long term. A medicine that requires fewer administrations could have practical advantages even when its weight-loss efficacy is not numerically the highest in every trial.
6. Body composition may become a core endpoint
The next stage of obesity medicine may increasingly focus on what type of weight is lost.
Preserving skeletal muscle, maintaining physical function and reducing visceral or ectopic fat may become increasingly important alongside total body-weight reduction.
This is particularly relevant for older adults and other populations in whom preservation of functional lean tissue is clinically important.
7. Cardiometabolic outcomes will matter increasingly
The modern obesity-treatment paradigm is expanding beyond weight loss.
Future clinical differentiation may involve evidence related to:
- cardiovascular events,
- heart failure,
- type 2 diabetes progression and control,
- obstructive sleep apnea,
- metabolic liver disease,
- kidney disease, and
- long-term functional outcomes.
A better way to monitor the obesity-drug race
Instead of maintaining a fixed “Top 10” list, an evidence-based obesity pipeline tracker should follow each medicine as an evolving entity.
A useful database structure is:
Company → Drug → Mechanism → Route → Dose → Trial → Population → Comparator → Duration → Weight Loss → Discontinuation → Adverse Events → Body Composition → Comorbidity Outcomes → Regulatory Status
This makes it possible to update the database whenever a Phase 2 readout, Phase 3 publication, regulatory submission or approval changes the evidence base.
One important rule: pipeline status is not clinical proof. A Phase 3 candidate with promising topline data remains different from an FDA-approved therapy with a mature evidence base.
Obesity Drug Competition 2026: the key takeaways
The obesity pharmaceutical market is moving from a relatively simple GLP-1 story toward a diversified metabolic-treatment ecosystem.
Eli Lilly is extending tirzepatide through oral GLP-1 therapy, triple agonism and amylin combinations.
Novo Nordisk is extending semaglutide through an oral formulation, higher-dose strategies and CagriSema and other amylin-based programs.
Roche and Zealand Pharma are developing an integrated GLP-1/GIP and amylin platform, including combinations.
Amgen is testing whether very long-acting treatment schedules can change the convenience equation.
Boehringer Ingelheim and Zealand Pharma are advancing glucagon/GLP-1 biology through survodutide.
AstraZeneca is pursuing a broad oral and multi-mechanism portfolio.
Regeneron is combining a GLP-1/GIP program with a broader metabolic strategy.
Viking Therapeutics is combining GLP-1/GIP development with oral and maintenance-dosing strategies.
Structure Therapeutics is pursuing oral small-molecule GLP-1 and amylin approaches.
Kailera and Hengrui illustrate the increasingly international nature of the obesity-drug pipeline.
The result is no longer a simple race that can be summarized responsibly by assigning each company a score from 1 to 10.
The more useful model is a multidimensional evidence map:
Mechanism + Efficacy + Tolerability + Route + Dosing Frequency + Durability + Body Composition + Comorbidity Outcomes + Manufacturing + Regulatory Status.
That framework is more transparent, more updateable and better suited to understanding where obesity medicine is heading as the field moves through the remainder of the 2020s.
Medical disclaimer: This article is for educational and informational purposes only. It does not constitute medical advice, diagnosis or treatment. Obesity medicines, including GLP-1 receptor agonists and investigational therapies, have contraindications, adverse effects, drug interactions and patient-selection considerations. Discuss treatment decisions with a qualified healthcare professional.
Frequently Asked Questions
What are the most important obesity-drug mechanisms in 2026?
The major categories include GLP-1 receptor agonism, GLP-1/GIP dual agonism, GLP-1/GIP/glucagon triple agonism, amylin-based therapy and combinations of these mechanisms. Oral small molecules and long-acting formulations represent additional technology strategies.
Is there a single best obesity drug in 2026?
There is no scientifically appropriate single ranking for all patients or all clinical situations. Treatment selection can depend on obesity severity, type 2 diabetes, cardiovascular disease, other comorbidities, tolerability, cost, route of administration, contraindications and individual treatment goals.
What is retatrutide?
Retatrutide is an investigational triple agonist targeting GIP, GLP-1 and glucagon receptors. Lilly reported substantial Phase 3 weight loss in 2026, but retatrutide remains investigational and should not be confused with an approved obesity medicine.
What is CagriSema?
CagriSema is an investigational once-weekly combination of semaglutide and the amylin analogue cagrilintide. Its Phase 3 program includes obesity and type 2 diabetes studies. Results have varied according to the clinical question and comparator, illustrating why cross-trial rankings can be misleading.
Are oral GLP-1 obesity drugs available?
Yes. In the United States, Novo Nordisk's oral Wegovy (semaglutide) was approved in December 2025 and launched in January 2026. Lilly's Foundayo (orforglipron) was approved in April 2026.
Why is amylin important in next-generation obesity drugs?
Amylin is a hormone involved in appetite regulation and energy balance. Several developers are investigating amylin analogues either alone or in combination with incretin therapies, creating a new generation of multi-mechanism obesity treatments.
Will obesity drugs eventually be given monthly instead of weekly?
Several investigational programs are testing monthly or less-frequent dosing. Whether these approaches become widely used will depend on clinical efficacy, tolerability, pharmacology, manufacturing and regulatory approval.
Why should obesity-drug rankings be treated cautiously?
Clinical trials differ in patient populations, trial duration, dose escalation, comparators, adherence and statistical methods. A higher percentage in one study does not automatically mean that the corresponding drug is more effective than a lower percentage reported in another study.
References and primary sources
- Fierce Pharma. Obesity Power Rankings: Who will challenge Lilly and Novo? February 23, 2026.
- U.S. FDA. FDA approves Foundayo (orforglipron). April 1, 2026.
- Novo Nordisk. Wegovy pill approved in the United States as the first oral GLP-1 for weight management. December 22, 2025.
- Novo Nordisk. Wegovy pill broadly available in America. January 5, 2026.
- Eli Lilly. Retatrutide Phase 3 TRIUMPH-1 results. May 21, 2026.
- Eli Lilly. EloraTZP Phase 2b results. September 30, 2026.
- Roche. CT-388 Phase 2 obesity results. January 27, 2026.
- Roche. Enicepatide Phase 2 results in type 2 diabetes and overweight/obesity. September 22, 2026.
- Zealand Pharma. Petrelintide pipeline information.
- Amgen. MariTide Phase 3 development update. August 2026.
- Boehringer Ingelheim. Survodutide SYNCHRONIZE-2 Phase 3 results. October 1, 2026.
- Regeneron. Olatorepatide Phase 3 results. March 9, 2026.
- Viking Therapeutics. VK2735 maintenance study. September 22, 2026.
- Structure Therapeutics. Aleniglipron and oral amylin program update. September 8, 2026.
- Hengrui Pharma and Kailera. Ribupatide clinical data. June 5, 2026.
Editorial note: Development-stage information can change rapidly. This article should be reviewed whenever a major regulatory decision, Phase 3 result or peer-reviewed publication materially changes the obesity-drug landscape.
Tools and Telehealth (Affiliate Links)
Affiliate disclosure: the links in this section are affiliate links. We may earn a commission if you buy or sign up, at no extra cost to you. They are convenience options, not medical recommendations.
- Virtual care: if you need a clinician to review your symptoms, labs or GLP-1 plan, The Wellness Company virtual care is one telehealth pathway. Availability, eligibility and prescribing decisions are determined by their licensed clinicians.
- Strength training at home: resistance band sets support the resistance-training advice above.
- Portion and protein tracking: a digital kitchen scale makes it easier to estimate protein per meal.
Related reading on GLP-1 Advisor and OneDayMD:
.png)
.png)
.png)
Comments